Clinical trials: Kennedy Disease
Prostatic Cancer, Castration-Resistant
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617)…
- Trial name
- NCT07047118
- Testing
- JSB462, AAA617
- Where
- 44 sites in United States, Australia and 13 more
- Volunteers
- 138 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer
Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
The goal of this clinical trial is to explore whether androgen deprivation therapy combined with novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide is superior to the current treatment…
- Trial name
- NCT06854250
- Testing
- Prostate cryoablation, Cyclophosphamide (CTX)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer Metastatic
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The aim of the study is to assess the clinical utility of 11C or 18F-Choline Positron Emission Tomography (PET)/Computed Tomography (CT) scan, Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and…
- Trial name
- NCT02815033
- Testing
- Enzalutamide, 11C or 18F-Choline PET/CT, Whole body MRI
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- The European Uro-Oncology Group
Triple Negative Breast Neoplasms
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.
- Trial name
- ABBICAR (NCT06365788)
- Testing
- Abemaciclib, Bicalutamide
- Where
- 6 sites in Belgium
- Volunteers
- 53 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Metastatic Castration Resistant Prostate Cancer
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy.
- Trial name
- NCT05673109
- Testing
- AC176
- Where
- 5 sites in China
- Volunteers
- 8 people
- Sponsor
- Accutar Biotechnology Inc
Acne Vulgaris
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Mechanism-based acne treatment for transgender patients receiving testosterone currently does not exist and is an unmet medical need. This study explores clascoterone to treat testosterone induced acne.
- Trial name
- NCT05891795
- Testing
- Clascoterone 1% Top Cream, Vehicle
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Breast Cancer
Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
This prospective, single center, phase II study is to evaluate the efficacy and safety of bicalutamide as a treatment in androgen receptor (AR)-positive metastatic triple-negative breast cancer (mTNBC) patients.
- Trial name
- NCT02348281
- Testing
- Bicalutamide
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Fudan University
Recurrent Glioblastoma, Recurrent High-grade Glioma
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
The goal of this study is to learn about a type of brain cancer called high-grade glioma. This study is for people who have previously received treatment for brain cancer, but the cancer has come back or gotten worse after…
- Trial name
- NCT06501911
- Testing
- Bicalutamide, Intensity-modulated radiation therapy (IMRT)
- Where
- United States
- Sponsor
- University of Nebraska
Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with…
- Conditions
- Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
- Trial name
- DIVINE (NCT06378866)
- Testing
- Abiraterone, Apalutamide, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 532 people
- Sponsor
- Mayo Clinic
Spinobulbar Muscular Atrophy, Kennedy's Disease
Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
This is a therapeutic trial study to demonstrate whether Goserelin, a LHRH agonist has benefit in SBMA Objective: 1. To study effects of Goserelin to clinical course of patients with spinal and bulbar muscular atrophy in Thailand…
- Trial name
- NCT00851461
- Testing
- Goserelin, Electrophysiologic study, tissue biopsy
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Ramathibodi Hospital
Spinal and Bulbar Muscular Atrophy
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
The purpose of this clinical trial is to evaluate the efficacy and safety of mexiletine hydrochloride in patients with spinal and bulbar muscular atrophy.
- Trial name
- Med-SBMA (NCT06862596)
- Testing
- Mexiletine hydrochloride
- Where
- 5 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Masahisa Katsuno
Prostate Cancer, Adenocarcinoma of Prostate
Mifepristone (RU-486) in Androgen Independent Prostate Cancer
The purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.
- Trial name
- NCT00140478
- Testing
- Mifepristone
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms, Castration-Resistant
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway…
- Trial name
- NCT07677267
- Where
- United States
- Volunteers
- 1,067 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Triple Negative Breast Cancer (TNBC)
An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC
This study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the LAR subtype.
- Trial name
- SCHBCC-N0117 (NCT07760844)
- Testing
- SHR- A1811+ eve, SHR- A1811
- Volunteers
- 180 people
- Sponsor
- Fudan University
Prostate Cancer, DNA
Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation
Rationale: Understanding the mechanisms of enzalutamide as an androgen receptor inhibitor in early prostate cancer could lead to improved patient selection for treatment.
- Conditions
- Prostate Cancer, DNA, Androgen Receptor Abnormal
- Trial name
- DARANA (NCT03297385)
- Testing
- Enzalutamide
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Prostatic Neoplasms
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
The purpose of this study is to assess the safety and pharmacokinetics of niraparib when administered in combination with an androgen receptor (AR)-targeted therapy (apalutamide or abiraterone acetate plus prednisone) in adult…
- Trial name
- NCT02924766
- Testing
- Niraparib, Apalutamide, Abiraterone Acetate
- Where
- 6 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine safety, including dose limiting toxicities, and the recommended phase 2 dose (RP2D) of EPI-7386 in separate combinations with (a) abiraterone acetate plus prednisone or prednisolone (AAP)…
- Trial name
- NCT05295927
- Testing
- EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone
- Where
- 4 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer
Bicalutamide in Treating Patients With Metastatic Breast Cancer
RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such as bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00468715
- Testing
- bicalutamide, diagnostic laboratory biomarker analysis, immunohistochemistry staining method
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukoencephalopathies, LBSL
Natural History Study of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)
In this study, we will conduct retrospective chart and imaging reviews and prospective longitudinal virtual assessments of individuals with LBSL.
- Conditions
- Leukoencephalopathies, LBSL, Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, White Matter Disease
- Trial name
- NCT03624374
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Behavior Disorders
Preventing Problems in Children's Social Behavior
Children who are at risk for problems in school may do better if they and their parents are taught how to communicate with each other between age 3 and 6 when the children enter kindergarten.
- Trial name
- NCT00006446
- Testing
- Training in parenting skills and communication
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)